Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF

The current study evaluated the effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF. 60 patients were randomized (1:1) to receive dapagliflozin 10 mg once daily, or placebo double blind for 1 year. Patients underwent transthoracic echo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Qianyu, Zhou, Longhua, Fan, Yuqin, Liu, Fenfen, Fan, Yuanyuan, Zhang, Xin, Wang, Li, Cheng, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633988/
https://www.ncbi.nlm.nih.gov/pubmed/37940879
http://dx.doi.org/10.1186/s12872-023-03591-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633988/
https://www.ncbi.nlm.nih.gov/pubmed/37940879
http://dx.doi.org/10.1186/s12872-023-03591-3

Ejemplares similares